Vivos Therapeutics Study Confirms OSA Correlation with Facial Morphology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Should l Buy VVOS?
Vivos Therapeutics announced that an a recent published study supports Vivos' long maintained belief that dental and facial morphology characterized by narrow palatal dental arches, high peaked palates, and recessed lower jaws were directly correlated to the prevalence and severity of obstructive sleep apnea, or OSA, in adults and children. Vivos CARE devices have been cleared by the FDA for adult patients diagnosed with mild, moderate and severe OSA and moderate-to-severe OSA in children ages 6 to 17. Many Vivos patients finish treatment in less than 12 months with little or no remaining OSA symptoms. The OSA group exhibited significantly narrower transverse intermolar distance and higher palatal height compared to the control group. Linear regression analysis demonstrated a strong association between these two key craniofacial parameters and OSA severity, as measured by the industry standard measure AHI. These results held true across all demographics.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VVOS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VVOS
Wall Street analysts forecast VVOS stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.150
Low
2.50
Averages
5.00
High
7.00
Current: 1.150
Low
2.50
Averages
5.00
High
7.00
About VVOS
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
New Show to Air Tonight on Bloomberg Television
- Global Broadcast Expansion: New to The Street's latest episode will air tonight at 6:30 PM EST on Bloomberg Television, extending its reach to the U.S., MENA, and Latin America, thereby enhancing international investor engagement and broadening its audience base.
- Biotech Advancements: BioVie Inc. is advancing a clinical trial for Parkinson's disease with 60 patients enrolled, expecting topline data in May 2026, which could significantly bolster its market position in the biopharmaceutical sector if successful.
- Obstructive Sleep Apnea Solutions: Vivos Therapeutics Inc.'s FDA-cleared non-surgical oral appliance aims to provide a long-term solution for the estimated one billion people affected by OSA globally, with strategic growth initiatives targeting direct-to-patient markets.
- Virtual Reality Market Growth: Virtuix Holdings Inc.'s Omni One platform has reported a 138% year-over-year growth in the gaming and fitness sectors, with production capacity supporting potential annual revenues of up to $100 million, indicating strong demand in both consumer and defense markets.
See More
Vivos Partners with SoundHealth to Launch Innovative Sleep Solutions
- Collaborative Technology Promotion: Vivos Therapeutics has partnered with SoundHealth to leverage its network of over 2,000 trained dentists and sleep healthcare providers to promote SoundHealth's Sonu® platform, aiming to enhance public awareness of airway and sleep health technologies.
- Product Innovation: The Sonu®Band is the world's first FDA-cleared AI-enabled wearable device that effectively treats nasal congestion without side effects and has been recognized as one of TIME's best inventions of 2025, expected to significantly enhance Vivos' product offerings and market competitiveness.
- Data-Driven Health Management: Vivos will utilize SoundHealth's CT-accurate facial scanning and voice biomarker technology to assist its clinical providers in more effectively screening and monitoring sleep disorder patients, thereby improving treatment outcomes and patient satisfaction.
- Significant Market Potential: With the global sleep technology market valued at approximately $30 billion, Vivos' collaboration will drive a shift from passive monitoring to active interventions, addressing the 80% of undiagnosed sleep-disordered breathing cases, which has critical social and economic implications.
See More
Oversold Stocks in Healthcare Sector Present Buying Opportunities
- Oversold Stocks Overview: In the healthcare sector, Zai Lab Ltd (NASDAQ:ZLAB), Vivos Therapeutics Inc (NASDAQ:VVOS), and Certara Inc (NASDAQ:CERT) are identified as oversold stocks, with RSI near or below 30, indicating potential for short-term rebounds.
- RSI Indicator Analysis: The Relative Strength Index (RSI) serves as a momentum indicator by comparing the strength of a stock on days it rises versus days it falls, helping traders assess short-term performance, with an RSI below 30 typically indicating oversold conditions.
- Investment Opportunity Assessment: In the current market environment, oversold stocks may present buying opportunities for investors looking to capitalize on undervalued companies, particularly in the healthcare sector, where sentiment shifts could lead to value recovery.
- Market Data Source: This information is based on data from Benzinga Pro, providing the latest list of oversold stocks in the healthcare sector to assist investors in identifying potential investment opportunities.
See More
Vivos Therapeutics Closes Exercise of 1.98M Warrants, Raising $4.64M
- Successful Financing: Vivos Therapeutics has successfully exercised 1,982,356 warrants, raising approximately $4.64 million, demonstrating the company's active presence in capital markets and enhancing its operational funding.
- New Warrants Issued: In exchange for cash exercise, the company issued 3,964,712 new warrants at an exercise price of $2.09 per share, which is expected to further improve the company's capital structure and financing flexibility.
- Market Positioning: Vivos focuses on treating obstructive sleep apnea (OSA) with its innovative devices cleared by the FDA, indicating significant market potential that is likely to attract more investor interest.
- Future Development Plans: The company intends to use the proceeds for working capital and general corporate purposes, reflecting its confidence in future growth and ability to seize market opportunities.
See More
Vivos Therapeutics (VVOS) Exercises Warrants for $4.64M in Funding
- Financing Agreement: Vivos Therapeutics has entered into an agreement for the immediate exercise of warrants, expected to raise approximately $4.64 million, indicating the company's active engagement in capital markets and funding capabilities.
- Warrant Details: The warrants exercised involve 1.98 million shares, with exercise prices reduced from $3.83 to $2.34, reflecting the company's adaptability to market conditions and commitment to shareholder value.
- New Warrants Issuance: As part of the transaction, Vivos will issue new warrants for 3.96 million shares at an exercise price of $2.09, enhancing investor participation and providing flexibility for future financing.
- Clear Use of Funds: The net proceeds from this offering will be used for working capital and general corporate purposes, demonstrating the company's strategic intent to expand operations and improve efficiency.
See More
Vivos Therapeutics CEO and CFO to Discuss Strategic Business Model on December 16, 2025
- Strategic Discussion: Vivos' CEO Kirk Huntsman and CFO Brad Amman will participate in a fireside chat on December 16, 2025, at 11:00 AM ET with Water Tower Research, discussing the company's business model pivot and market opportunities, aiming to enhance investor confidence in future growth.
- Market Opportunity Analysis: The discussion will cover Vivos' market opportunities in treating obstructive sleep apnea (OSA), which affects over 1 billion people globally, with 90% undiagnosed, highlighting significant potential for growth and expansion.
- Innovative Treatment Methods: Vivos' Complete Airway Repositioning and Expansion (CARE) devices are the only FDA-cleared technology for treating severe OSA in adults, marking the company's leadership in non-surgical, non-invasive treatment, which could drive future revenue growth.
- Future Outlook: By collaborating with sleep healthcare providers, Vivos aims to address the complex needs of OSA patients, which is expected to further enhance its market competitiveness and financial performance, driving sustainable long-term growth.
See More
New Show to Air Tonight on Bloomberg Television
- Global Broadcast Expansion: New to The Street's latest episode will air tonight at 6:30 PM EST on Bloomberg Television, extending its reach to the U.S., MENA, and Latin America, thereby enhancing international investor engagement and broadening its audience base.
- Biotech Advancements: BioVie Inc. is advancing a clinical trial for Parkinson's disease with 60 patients enrolled, expecting topline data in May 2026, which could significantly bolster its market position in the biopharmaceutical sector if successful.
- Obstructive Sleep Apnea Solutions: Vivos Therapeutics Inc.'s FDA-cleared non-surgical oral appliance aims to provide a long-term solution for the estimated one billion people affected by OSA globally, with strategic growth initiatives targeting direct-to-patient markets.
- Virtual Reality Market Growth: Virtuix Holdings Inc.'s Omni One platform has reported a 138% year-over-year growth in the gaming and fitness sectors, with production capacity supporting potential annual revenues of up to $100 million, indicating strong demand in both consumer and defense markets.
See More
Vivos Partners with SoundHealth to Launch Innovative Sleep Solutions
- Collaborative Technology Promotion: Vivos Therapeutics has partnered with SoundHealth to leverage its network of over 2,000 trained dentists and sleep healthcare providers to promote SoundHealth's Sonu® platform, aiming to enhance public awareness of airway and sleep health technologies.
- Product Innovation: The Sonu®Band is the world's first FDA-cleared AI-enabled wearable device that effectively treats nasal congestion without side effects and has been recognized as one of TIME's best inventions of 2025, expected to significantly enhance Vivos' product offerings and market competitiveness.
- Data-Driven Health Management: Vivos will utilize SoundHealth's CT-accurate facial scanning and voice biomarker technology to assist its clinical providers in more effectively screening and monitoring sleep disorder patients, thereby improving treatment outcomes and patient satisfaction.
- Significant Market Potential: With the global sleep technology market valued at approximately $30 billion, Vivos' collaboration will drive a shift from passive monitoring to active interventions, addressing the 80% of undiagnosed sleep-disordered breathing cases, which has critical social and economic implications.
See More
Oversold Stocks in Healthcare Sector Present Buying Opportunities
- Oversold Stocks Overview: In the healthcare sector, Zai Lab Ltd (NASDAQ:ZLAB), Vivos Therapeutics Inc (NASDAQ:VVOS), and Certara Inc (NASDAQ:CERT) are identified as oversold stocks, with RSI near or below 30, indicating potential for short-term rebounds.
- RSI Indicator Analysis: The Relative Strength Index (RSI) serves as a momentum indicator by comparing the strength of a stock on days it rises versus days it falls, helping traders assess short-term performance, with an RSI below 30 typically indicating oversold conditions.
- Investment Opportunity Assessment: In the current market environment, oversold stocks may present buying opportunities for investors looking to capitalize on undervalued companies, particularly in the healthcare sector, where sentiment shifts could lead to value recovery.
- Market Data Source: This information is based on data from Benzinga Pro, providing the latest list of oversold stocks in the healthcare sector to assist investors in identifying potential investment opportunities.
See More
Vivos Therapeutics Closes Exercise of 1.98M Warrants, Raising $4.64M
- Successful Financing: Vivos Therapeutics has successfully exercised 1,982,356 warrants, raising approximately $4.64 million, demonstrating the company's active presence in capital markets and enhancing its operational funding.
- New Warrants Issued: In exchange for cash exercise, the company issued 3,964,712 new warrants at an exercise price of $2.09 per share, which is expected to further improve the company's capital structure and financing flexibility.
- Market Positioning: Vivos focuses on treating obstructive sleep apnea (OSA) with its innovative devices cleared by the FDA, indicating significant market potential that is likely to attract more investor interest.
- Future Development Plans: The company intends to use the proceeds for working capital and general corporate purposes, reflecting its confidence in future growth and ability to seize market opportunities.
See More
Vivos Therapeutics (VVOS) Exercises Warrants for $4.64M in Funding
- Financing Agreement: Vivos Therapeutics has entered into an agreement for the immediate exercise of warrants, expected to raise approximately $4.64 million, indicating the company's active engagement in capital markets and funding capabilities.
- Warrant Details: The warrants exercised involve 1.98 million shares, with exercise prices reduced from $3.83 to $2.34, reflecting the company's adaptability to market conditions and commitment to shareholder value.
- New Warrants Issuance: As part of the transaction, Vivos will issue new warrants for 3.96 million shares at an exercise price of $2.09, enhancing investor participation and providing flexibility for future financing.
- Clear Use of Funds: The net proceeds from this offering will be used for working capital and general corporate purposes, demonstrating the company's strategic intent to expand operations and improve efficiency.
See More
Vivos Therapeutics CEO and CFO to Discuss Strategic Business Model on December 16, 2025
- Strategic Discussion: Vivos' CEO Kirk Huntsman and CFO Brad Amman will participate in a fireside chat on December 16, 2025, at 11:00 AM ET with Water Tower Research, discussing the company's business model pivot and market opportunities, aiming to enhance investor confidence in future growth.
- Market Opportunity Analysis: The discussion will cover Vivos' market opportunities in treating obstructive sleep apnea (OSA), which affects over 1 billion people globally, with 90% undiagnosed, highlighting significant potential for growth and expansion.
- Innovative Treatment Methods: Vivos' Complete Airway Repositioning and Expansion (CARE) devices are the only FDA-cleared technology for treating severe OSA in adults, marking the company's leadership in non-surgical, non-invasive treatment, which could drive future revenue growth.
- Future Outlook: By collaborating with sleep healthcare providers, Vivos aims to address the complex needs of OSA patients, which is expected to further enhance its market competitiveness and financial performance, driving sustainable long-term growth.
See More
